GTX Stock Price, News & Analysis (NASDAQ:GTXI) Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$1.20MA: $4.77▼$7.2052-Week Range N/AVolumeN/AAverage Volume390,540 shsMarket Capitalization$28.86 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GTXI Previous Symbol CUSIP40052B10 CIK1260990 Webhttp://www.gtxinc.com/ Phone901-523-9700Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-38,420,000.00 Net MarginsN/A Return on Equity-104.19% Return on Assets-86.42%Miscellaneous Employees21 Outstanding Shares24,050,000Market Cap$28.86 million Next Earnings DateN/A OptionableOptionable Receive GTXI News and Ratings via Email Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. GTX (NASDAQ:GTXI) Frequently Asked Questions What is GTX's stock symbol? GTX trades on the NASDAQ under the ticker symbol "GTXI." How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) issued its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.09. View GTX's Earnings History. Has GTX been receiving favorable news coverage? Headlines about GTXI stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. GTX earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for GTX. Who are some of GTX's key competitors? Some companies that are related to GTX include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). What other stocks do shareholders of GTX own? Based on aggregate information from My MarketBeat watchlists, some companies that other GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Novavax (NVAX), NovaBay Pharmaceuticals (NBY), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Arena Pharmaceuticals (ARNA), Catalyst Pharmaceuticals (CPRX) and MEI Pharma (MEIP). Who are GTX's key executives? GTX's management team includes the folowing people: Dr. Robert James Wills B.S., M.S., Ph.D., Exec. Chairman (Age 65)Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)Dr. Diane C. Young, VP & Chief Medical Officer (Age 62) How big of a company is GTX? GTX has a market capitalization of $0.00. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. GTX employs 21 workers across the globe.View Additional Information About GTX. What is GTX's official website? The official website for GTX is http://www.gtxinc.com/. How can I contact GTX? GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected] MarketBeat Community Rating for GTX (NASDAQ GTXI)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 491MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/23/2019 by MarketBeat.com StaffFeatured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?